Vancomycin utilization evaluation at hematology-oncology ward of a teaching Hospital in Iran

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 1, 2012, Pages 163-170

  Vazin, Afsaneh ^a   Japoni, Aziz ^b   Shahbazi, Sakineh ^a   Davarpanah, Mohammad Ali ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Appropriate drug use; Drug utilization research; Serum concentration; Vancomycin

Indexed keywords

AMIKACIN; AMPHOTERICIN B; CEFEPIME; CEFTAZIDIME; CREATININE; IMIPENEM; VANCOMYCIN;

ABSCESS; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; CELLULITIS; CREATININE BLOOD LEVEL; DILUTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG UTILIZATION; ENDOCARDITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUORESCENCE POLARIZATION IMMUNOASSAY; GLOMERULUS FILTRATION RATE; HEMATOLOGY; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; INFUSION RATE; IRAN; KIDNEY FAILURE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; NEPHROTOXICITY; ONCOLOGY; OSTEOMYELITIS; PERICARDITIS; PNEUMONIA; PRACTICE GUIDELINE; SEPSIS; TEACHING HOSPITAL; TREATMENT DURATION; WARD;

EID: 84858606245     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin. Infect. Dis. (2006) 42: 3-4.
2. Timmers GJ, van der Zwet WC, Simoons-Smit IM, Savelkoul PH, Meester HH, Vandenbroucke-Grauls CM and Huijgens PC. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br. J. Haematol. (2002) 116: 826-833.
3. Chadwick PR, Oppenheim BA, Fox A, Woodford N, Morgenstern GR and Scarffe JH. Epidemiology of an outbreak due to glycopeptide-resistant Enterococcus faecium on a leukaemia unit. J. Hosp. Infect. (1996) 34: 171-182.
4. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF and Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. (2004) 29: 3-14.
5. Naas T, Fortineau N, Snanoudj R, Spicq C, Durrbach A and Nordmann P. First nosocomial outbreak of vancomycin-resistant Enterococcus faecium expressing a VanD-like phenotype associated with a vanA genotype. J. Clin. Microbiol. (2005) 43: 3642-3649.
6. Askarian M, Afkhamzadeh R, Monabbati A, Daxboeck F and Assadian O. Risk factors for rectal colonization with vancomycin-resistant enterococci in Shiraz, Iran. Int. J. Infect. Dis. (2008) 12: 171-175.
7. Askarian M, Assadian O, Safaee G, Golkar A, Namazi S and Movahed MR. Vancomycin use in a large teaching hospital in Shiraz, Islamic Republic of Iran. East Mediterr. Health J. (2007) 13: 1195-1201.
8. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA and Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin. Infect. Dis. (2011) 52: e56-93.
9. Hospital Infection Control Practice Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect. Control Hosp. Epidemiol. (1995) 16: 105-113.
10. Niederman MS. Principles of appropriate antibiotic use. Int. J. Antimicrob. Agents (2005) 26: 170-175.
11. You JH, Lyon DJ, Lee BS, Kwan SM and Tang HY. Vancomycin utilization at a teaching hospital in Hongkong. Am. J. Health-sys. Pharm. (2001) 58: 2167-2169.
12. Hing WC, Bek SJ, Lin RT and Li SC. A retrospective drug utilization evaluation of vancomycin usage in paediatric patients. J. Clin. Pharm. Ther. (2004) 29: 359-365.
13. Bianco A, Rizza P, Scaramuzza G and Pavia M. Appropriateness of glycopeptide use in a hospital in Italy. Int. J. Antimicrob. Agents (2006) 27: 113-119.
14. Drinkovic D, Taylor SL, Pottumarthy S and Morris AJ. Prospective vancomycin audit in Auckland healthcare hospitals. N Z Med. J. (1999) 112: 336-339.
15. Evans ME and Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect. Control Hosp. Epidemiol. (1996) 17: 356-359.
16. Alfandari S, Levent T, Descamps D, Hendricx S, Bonenfant C, Taines V, Cattoen C, Arimane O and Grandbastien B. Evaluation of glycopeptide use in nine French hospitals. Med. Mal. Infect. (2010) 40: 232-237.
17. Roustit M, François P, Sellier E, Roch N, Vittoz JP, Foroni L, Stahl JP and Pavese P. Evaluation of glycopeptide prescription and therapeutic drug monitoring at a university hospital. Scand. J. Infect. Dis. (2010) 42: 177-184.
18. Melo DO and Ribeiro E. Vancomycin use in a Brazilian teaching hospital: comparison with the Hospital Infection Control practices Advisory Committee Guidelines (HICPAC). Braz. J. Infect. Dis. (2009) 13: 161-164.
19. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N. Engl. J. Med. (1993) 328:1323-1332.
20. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA and Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect. Dis. (2005) 5: 431-439.
21. Paul M, Borok S, Fraser A, Vidal L, Cohen M and Leibovici L. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. The Cochrane Database Syst. Rev. (2005) 20: CD003914.
22. Paul M, Borok S, Fraser A, Vidal L and Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. (2005) 55: 436-444.
23. Aoun M. Review: Additional anti-Gram-positive antibiotics do not reduce all-cause mortality in cancer and febrile neutropenia. ACP J. Club (2006) 144: 3.
24. Darko W, Medicis JJ and Smith A. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy (2003) 23: 643-650.
25. Wilhelm MP and Estes L. Symposium on antimicrobial agents-part XII. Vancomycin. Mayo Clinic Proc. (1999) 74: 928-935.
26. Rybak MJ and Boike SC. Monitoring vancomycin therapy. Drug Intell. Clin. Pharm. (1986) 20: 757-761.
27. Sorrell TC and Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J. Antimicrob. Chemother. (1985) 16: 235-241.
28. Hailemeskel B, Namanny M and Wutoh A. Frequency of nephrotoxicity with vancomycin and aminoglycoside therapy. Hosp. Pharm. (1999) 34: 1417-1420.
29. Salama SE and Rotstein C. Prospective assessment of nephrotoxicity with concomitant aminoglycoside and vancomycin therapy. Can. J. Hosp. Pharm. (1993) 46: 53-59.
30. Hahn-Ast C, Glasmacher A, Arns A, Mühling A, Orlopp K, Marklein G and Von Lilienfeld-Toal M. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant? Infection (2008) 36: 54-58.
31. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR and Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. (2009) 49: 325-327.
32. LaPlante KL, Leonard SN, Andes DR, Craig WA and Rybak MJ. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in-vitro pharmacodynamic models. Antimicrob. Agents Chemother. (2008) 52: 2156-2162.
33. Moise-Broder PA, Sakoulas G, Eliopoulos GM Schentag JJ, Forrest A and Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillinresistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. (2004) 38:1700-1705.